Ibrutinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4285 publications

Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis.

Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis.

Journal: Leukemia & lymphoma

Published: April 11, 2026

Ibrutinib: 10 years and counting.

Ibrutinib: 10 years and counting.

Journal: Blood

Published: April 09, 2026

Pharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumors.

Pharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumors.

Journal: Science translational medicine

Published: April 08, 2026

Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review.

Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review.

Journal: Leukemia & lymphoma

Published: April 08, 2026

Suspected Secondary Intraocular Lymphoma With Choroidal Involvement Following Testicular Diffuse Large B-cell Lymphoma: A Case Report.

Suspected Secondary Intraocular Lymphoma With Choroidal Involvement Following Testicular Diffuse Large B-cell Lymphoma: A Case Report.

Journal: Cureus

Published: April 07, 2026

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Journal: Pharmacological research

Published: March 31, 2026

HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.

HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

IgG-κ lymphoplasmacytic lymphoma complicated by bilateral femoral neck fractures secondary to bone involvement

IgG-κ lymphoplasmacytic lymphoma complicated by bilateral femoral neck fractures secondary to bone involvement

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 29, 2026

Inflation Reduction Act impact on the hematology/oncology treatment landscape.

Inflation Reduction Act impact on the hematology/oncology treatment landscape.

Journal: The American journal of managed care

Published: March 26, 2026

Precision targeting of BTK in chronic lymphocytic leukemia: computational insights into structural dynamics and the influence of mutations on BTK inhibitors through QM and MM studies.

Precision targeting of BTK in chronic lymphocytic leukemia: computational insights into structural dynamics and the influence of mutations on BTK inhibitors through QM and MM studies.

Journal: Journal of biomolecular structure & dynamics

Published: March 23, 2026

Novel Deiodinase 2-Selective Inhibitors-Possible Reference Substances for Regulatory In Vitro Tests for Endocrine Disruptors and Drugs Targeting T3-Dependent Processes.

Novel Deiodinase 2-Selective Inhibitors-Possible Reference Substances for Regulatory In Vitro Tests for Endocrine Disruptors and Drugs Targeting T3-Dependent Processes.

Journal: Thyroid : official journal of the American Thyroid Association

Published: March 13, 2026

Burger JA, Barr PM, Robak T, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood. 2025;146(18):2168-2176.

Burger JA, Barr PM, Robak T, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood. 2025;146(18):2168-2176.

Journal: Blood

Published: March 05, 2026

Showing 1-12 of 4,285

Last Updated: 04/28/2026